SCHEMBL28619296

SCHEMBL28619296

NC(=O)O[C@H]1CCCC[C@@H]1NS(=O)(=O)c1ccc([N+](=O)[O-])cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.47
NPSR1 Q6W5P4 1/20 0.47
THRB P10828 1/20 0.46
MAPK1 P28482 1/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
LMNA P02545 3/20 0.45
POLB P06746 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
F2 P00734 2/20 0.44
PRSS1 P07477 2/20 0.44
PRSS2 P07478 2/20 0.44
PRSS3 P35030 2/20 0.44
CA1 P00915 2/20 0.43
CA2 P00918 2/20 0.43
MMP1 P03956 1/20 0.43
MMP2 P08253 1/20 0.43
MMP9 P14780 1/20 0.43
MMP8 P22894 1/20 0.43
MMP13 P45452 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30221947 0.80 MEN1 (0.59) ALDH1A1NPSR1MAPK1MEN1KMT2A
SCHEMBL21994678 0.78 MEN1 (0.51) ALDH1A1NPSR1MEN1KMT2ALMNA
SCHEMBL810108 0.78 MEN1 (0.51) ALDH1A1NPSR1MEN1KMT2ALMNA
SCHEMBL21994368 0.78 MEN1 (0.48) ALDH1A1MEN1KMT2APOLBTDP1
SCHEMBL30065513 0.74 ALOX5 (0.46) ALDH1A1NPSR1MEN1KMT2ALMNA
SCHEMBL20271516 0.73 SMN1; SMN2 (0.73) ALDH1A1MAPK1MEN1KMT2ALMNA
Bicarbonate SCHEMBL15226074 0.73 SMN1; SMN2 (0.63) ALDH1A1MAPK1MEN1KMT2ALMNA
SCHEMBL15225951 0.72 SMN1; SMN2 (0.71) ALDH1A1MAPK1MEN1KMT2ALMNA
SCHEMBL32674342 0.72 CA2 (0.47) ALDH1A1NPSR1MEN1KMT2APOLB
SCHEMBL31062539 0.71 MEN1 (0.46) MEN1KMT2APOLBTDP1F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113166101-A Cyclic pentameric compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders 诺华股份有限公司 2021-07-23 CN disclosed